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ORIGINAL RESEARCH
Abstract: The introduction of topical calcineurin inhibitors resulted in a significant
improvement in the treatment of atopic dermatitis. In addition, rapid amelioration of pruritus
could be observed. In case reports, other pruritic dermatoses such as chronic irritative hand
dermatitis, rosacea, graft-versus-host-disease, and lichen sclerosus were also treated
successfully with pimecrolimus and tacrolimus. Twenty patients were treated with tacrolimus
and pimecrolimus in a surveillance study to evaluate efficacy in pruritus and prurigo. Eighteen
of 20 patients responded to therapy. Best results were obtained in localized and generalized
pruritus while in prurigo nodularis only a subgroup of patients showed an improvement of
pruritus. Further controlled studies are necessary to confirm these results.
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Introduction
Chronic pruritus is frequently resistant to common therapeutic regimens and demands
new approaches (Ständer, Steinhoff, Schmelz, et al 2003; Weisshaar et al 2003).
Therefore, the current neurophysiological and neuromorphological research (Ständer,
Steinhoff, Schmelz, et al 2003; Greaves and Khalifa 2004) focuses on this problem.
Up to now, it is known that pruritus can be evoked by mediators such as histamine,
neuropeptides, proteinases, prostaglandins, serotonin, and bradykinin (Schmelz 2002;
Ständer, Steinhoff, Schmelz, et al 2003). Moreover, current investigations identified
new receptor systems on cutaneous sensory nerve fibers such as vanilloid, opioid,
and cannabinoid receptors that can modulate itch and thereby represent targets for
antipuritic therapy (Ständer et al 2002, 2004, 2005). Interestingly, the vanilloid
receptor TRPV1 induces burning itch upon short-term activation while chronic
stimulation leads to the interruption of nociceptive transmission to the central nervous
system (Caterina et al 1997; Ständer et al 2001). In current studies there is indirect
evidence that next to capsaicin also the calcineurin inhibitors may bind to the TRPV1
(Ständer, Steinhoff, Ständer, et al 2003; Senba et al 2004). Based on this theory, it
may be speculated that pimecrolimus and tacrolimus may not only suppress pruritus
in atopic dermatitis but also in other pruritic diseases. In this paper we report for the
first time on the efficacy of topical calcineurin inhibitors in diseases such as prurigo
nodularis, generalized and localized pruritus including genitoanal pruritus. 20 patients
(12 female, 8 male; 26 to 76 years, mean age 55.9 years) with generalized (n = 3) and
localized (n = 2; lower legs, n = 1; back, n = 1) pruritus, pruritus of the genitoanal
area (n = 4; scrotal, n = 2; vulva, n = 1; anal, n = 1), and prurigo nodularis (n = 11)
were treated with pimecrolimus 1% cream and tacrolimus 0.1% ointment. Patients
had been suffering from pruritus since 5 months up to 20 years (mean, 4.2 years; 5
months, n = 1; 6 months, n = 2; 11 months, n = 1; 1 year, n = 2; 18 months, n = 1; 20
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Table 1 Antipruritic effect in chronic pruritus and prurigo: patients, applied calcineurin inhibitor, and outcome
Antipruritic effect
Diagnosis/duration Type of Duration in percent reduction Influence on
Age, sex of disease calcineurin inhibitor of therapy of itch skin lesions
Pruritus
52 years, male Generalized pruritus/since 10 years Tacrolimus 0.1% 11 months 70% reduction None present
74 years, male Generalized pruritus/10 years Pimecrolimus 1% 3 months 50% reduction None present
69 years, female Generalized pruritus/2 years Pimecrolimus 1% 14 days 90% reduction None present
37 years, male Pruritus lower legs/4 years Pimecrolimus 1% 1 month 100% reduction None present
76 years, female Pruritus on the back/1 year Pimecrolimus 1% 1 month 50% reduction None present
Genitoanal pruritus
63 years, male Genital pruritus/6 months Tacrolimus 0.1% 7 months 100% reduction None present
31 years, female Genital pruritus with lichen Pimecrolimus 1% 24 months 100% reduction Healing*
simplex/14 years
72 years, male Scrotal pruritus/2 years Pimecrolimus 1% 6 months 100% reduction None present
39 years, male Anal pruritus/1 year Pimecrolimus 1% 1 month 100% reduction None present
Prurigo nodularis
28 years, female Prurigo nodularis/5 years Tacrolimus 0.1% 3 months 100% reduction Healing
74 years, female Prurigo nodularis/6 months Pimecrolimus 1% 16 months 100% reduction Healing
63 years, female Prurigo nodularis/20 years Pimecrolimus 1% 5 months 100% reduction Healing
54 years, male Prurigo nodularis/20 months Pimecrolimus 1% 25 months 70% reduction Improvement
54 years, female Prurigo nodularis/22 months Pimecrolimus 1% 7 months 70% reduction Improvement
74 years, female Prurigo nodularis/2 years Pimecrolimus 1% 6 months 50% reduction Improvement
51 years, female Prurigo nodularis/11 months Tacrolimus 0.1% 3 weeks 50% reduction Improvement
48 years, female Prurigo nodularis/3 years Pimecrolimus 1% 3 weeks 20% reduction Minor
improvement*
26 years, female Prurigo nodularis/5 months Tacrolimus 0.1% 2 months 20% reduction Minor
improvement
73 years, male Prurigo nodularis/18 months Pimecrolimus 1% 8 days No response No response
55 years, female Prurigo nodularis/3 years Tacrolimus 0.1% 3 weeks No response No response
*Improvement: healing between 50% to 70% of skin lesions, minor improvement: healing up to 50% of skin lesions
months, n = 1; 22 months, n = 1; 2 years, n = 3; 3 years, n = 2;
4 years, n = 1; 5 years, n = 1; 10 years, n = 2; 14 years, n = 1;
20 years, n = 1).
The underlying origin could be identified in 12 patients:
a combination (5 patients) or single (7 patients) presence of
psychogenic factors (n = 5), deficiency of vitamins (n = 6,
iron, n = 1; zinc, n = 4; and vitamin B12, n = 1), helicobacter
infection of the stomach (n = 2), diabetes mellitus (n = 1),
xerosis in elderly (n = 2), atopic predisposition (n = 6;
without atopic eczema) led to the itch. In 8 patients, no
underlying cause could be identified. The intense and
chronic pruritus leads in 11 patients to the clinical picture
of prurigo nodularis with flat or prominent erosive and
crusted papules and nodules. All patients with localized,
generalized, and genitoanal pruritus had no or minimal linear
scratch lesions, except of one female patient with
lichenification in the genial area.
Pruritus was therapy refractory to topical (n = 14) and
systemical corticosteroids (n = 3), antihistamines (n = 9), UV-
therapy (n = 8), moisturing the skin (n = 5), capsaicin (n = 2),
opiate receptor antagonists (n = 1), serotonin reuptake
inhibitors (n = 1), antiparasital and antifungal therapies
(n = 6).
All patients received topical calcineurin inhibitors in an
open uncontrolled surveillance study. All patients were
informed about pimecrolimus and tacrolimus and that they
are already commercially available for atopic dermatitis.
Patients applied the topical twice daily; no other topical or
systemical antipruritic therapy was allowed. As according
to the current literature most patients were treated for
pruritus with tacrolimus, we applied tacrolimus in 6 patients
only while 14 were treated with pimecrolimus. In each
diagnosis group, at least one patient was treated with
tacrolimus to control that pruritus responds to this substance.
In the large group of prurigo nodularis, 4 patients with
different stage of the disease received tacrolimus. The
patients were seen every 4 weeks and were investigated
clinically for presence and expansion of skin lesions. The
antipruritic effect was evaluated as follows: the itch intensity
before starting therapy was rated as 100%. Then all patients
were asked to quote the itch reduction in percent during the
therapy (eg, if itch intensity was reduced about half, it wasTherapeutics and Clinical Risk Management 2006:2(2) 215
Pruritic diseases and calcineurin inhibitors
scored as 50% itch reduction). In prurigo nodularis,
photographic documentation was performed.
Results
Eighteen of the 20 patients responded to therapy; 2 patients
(10%) did not report any antipruritic effect. A complete
reduction of itch (100% itch reduction) was achieved in 8
patients (40%); an almost complete cessation (70% itch
reduction, n = 3; 90% itch reduction, n=1) was observed in
4 patients (20%). An itch reduction of 50% was reported by
4 patients (20%) while 2 patients (10%) showed almost no
improvement of itch (20% itch reduction). The mean itch
reduction in all patients was 67%.
Best response was achieved in genitoanal pruritus. All
patients experienced a complete reduction of pruritus using
pimecrolimus (n = 3) or tacrolimus (n = 1). Patients reported
a rapid cessation of itch within the initial three days of
treatment. In a patient with additional lichenification due to
chronic scratching, all lesions resolved.
In generalized and localized pruritus, a good reduction
of pruritus was observed (mean itch reduction: 72%). Three
of 5 patients responded with complete (n = 1) or nearly
complete (n = 2) relief of itch. Pruritus was reduced to 50%
in additional 2 patients. These results were similar in using
tacrolimus or pimecrolimus; tacrolimus achieved a reduction
of 70% in one patient; pimecrolimus a mean reduction of
72.5% in 4 patients. In prurigo nodularis, a complete relief
(100%) or almost complete cessation (70%) of itch and
healing or major improvement of the lesions was achieved
in 5 patients (tacrolimus, n = 1; pimecrolimus, n = 4). In 2
other patients, tacrolimus and pimecrolimus achieved a 50%
reduction of itch, respectively. In 4 other patients, both
calcineurin inhibitors showed only weak (20%, n = 2) or no
(n = 2) antipruritic effect without improvement of skin
lesions. The average itch reduction in prurigo nodularis was
53%.
Pimecrolimus and tacrolimus were applied individually
up to the maximal achievable relief of the itch and clearance
of all skin lesions. The duration of therapy varied from 14
days to 11 months (mean, 7.3 months; 14 days, n = 1; 3
weeks, n = 1; 1 month, n = 3; 3 months, n = 2; 5 months, n = 1;
6 months, n = 2; 7 months, n = 2; 11 months, n = 1; 16 months,
n = 1, 2 years, n = 2). In the group of no or weak response
(up to 30% pruritus reduction and less), therapy was stopped
after 8 days (n = 1), 3 weeks (n = 2), or 2 months (n = 1).
All patients with application of the calcineurin inhibitors
in the genital area reported an intense burning in the first
two to three days. After these initial days the burning stops.
In the other two groups, only single patients treated with
either pimecrolimus or tacrolimus complained on initial
burning. No other side effects appear.
Discussion
The development of topical calcineurin inhibitors resulted
in a significant improvement in the treatment of atopic
dermatitis (Simpson and Noble 2005). Parallel to the rapid
reduction of eczematous lesions, fast relief of pruritus was
observed (Meurer et al 2002; Reitamo et al 2002; Ständer
and Luger 2003). The antipruritic effect is currently believed
to be related to the inhibition of inflammatory cytokines
(Bornhövd et al 2002). Pimecrolimus and tacrolimus
primarily induce calcineurin inhibition that interrupts
cytokine gene expression and leads to the down regulation
of T-cell activity. Furthermore, recent investigations suggest
that calcineurin inhibitors may also directly influence nerve
fiber function by possible binding to a receptor on small,
unmyelinated sensory nerve fibers, the TRPV1 (VR1,
capsaicin receptor) (Ständer, Steinhoff, Ständer, et al 2003;
Figure 1 Female 74-year old patient with prurigo nodularis since 6 months (a).
After a therapy of 12 months all lesions of the arm cleared (b).
(a)
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Senba et al 2004). After activation of this receptor eg, by
capsaicin, nerve fibers are depolarized resulting in
transmission of burning pain and itch and the release of
neuropeptides. Along with continuous stimulation of the
TRPV1, the receptor is finally desensitized and the
transmission of nociceptive stimuli is inhibited. These
findings may provide a possible explanation for the observed
calcineurin inhibitors-related side-effects such as initial
burning and pruritus, and moreover, the following rapid
reduction of pruritus.
Previously, a complete relief of pruritus under twice daily
topical tacrolimus 0.1% therapy was reported in a patient
with severe pruritus induced by primary biliary cirrhosis
(Aguilar-Bernier et al 2005) (Table 2). Tacrolimus
application in uremic pruritus led to conflicting results.
While in a case report with single patients (Pauli-Magnus
et al 2000) and in a prospective study with two sequential
concentrations of tacrolimus (0.03%, 0.1%) ointment
(Kuypers et al 2004) this substance led to significant
reduction of itch in uremic pruritus, a randomized, double-
blind, vehicle-controlled study did not demonstrate that
tacrolimus ointment 0.1% is more effective than its vehicle
in relieving uremic pruritus (Duque et al 2005).
Several reports also demonstrate the antipruritic efficacy
of the topical immunomodulators in dermatological diseases.
For example, a patient with epidermolysis bullosa
pruriginosa was treated with tacrolimus 0.03% for otherwise
intractable itching on the legs and experienced a relief within
one week (Banky et al 2004). Patients with chronic irritative
hand dermatitis experienced significant reduction of itch
during topical treatment with pimecrolimus 1% (Cherill et
al 2000). In pruritus of steroid-induced rosacea (Goldmann
2001), chronic graft-versus-host-disease (Choi and Nghiem
2001), and lichen sclerosus et atrophicus (Böhm et al 2003),
case reports demonstrated antipruritic efficacy of tacrolimus
0.075%–0.1% therapy within 7 to 10 days (Table 2).
In the current surveillance study, the antipruritic potency
of calcineurin inhibitors in prurigo nodularis, generalized
and localized pruritus including genitoanal pruritus was
evaluated. Since most of the previous reports demonstrated
convincing antipruritic effects of tacrolimus application, we
focussed on topical pimecrolimus therapy. All investigated
diagnoses showed a response to topical therapy with
tacrolimus and pimecrolimus. A continuous significant
antipruritic effect was obtained in genitoanal pruritus with
either tacrolimus or pimecrolimus. Patients reported on fast
reduction of itch (after 2 to 3 days) after cessation of initial
burning. Genitoanal pruritus is a frequent, localized form
of pruritus mostly induced by infections (eg, candidiasis),
helminths, hemorrhoids, or genital dermatological diseases
Table 2 Antipruritic effect of calcineurin inhibitors in pruritic diseases reported in case reports, case series, uncontrolled, and
controlled studies
Number of Topical Reduction
Author Diagnosis patients Immunomodulator of itch
Aguilar-Bernier et al 2005 Pruritus in primary Tacrolimus 0.1%, 100% relief within
biliary cirrhosis 1 twice daily 1month, QoL improved
Pauli-Magnus et al 2000 Uremic pruritus 3 Tacrolimus 0.03%, twice daily 100% relief within 2 days
Cherill et al 2000 Chronic- irritative  48 Pimecrolimus 1% Significant reduction
hand eczema
Goldman 2001 Steroid-induced rosacea 3 Tacrolimus 0.075% 100% relief within 7 to 10
days
Choi and Nghiem, 2001 Chronic GvhD 18 Tacrolimus 0.1% Reduction in 13 patients
Böhm et al 2003 Genitoanal lichen 3 children Tacrolimus 0.1% Significant reduction
sclerosus et atrophicus (5–9 years) within 8 days
3 adults
Banky et al 2004 Epidermolysis bullosa 1 Tacrolimus 0.03%, twice daily 100% relief within
pruriginosa 1 week, scratch marks
reduced
Kuypers et al 2004 Uremic pruritus 21 Tacrolimus 0.1% (3 weeks) 81.8% reduction
then 0.03% (3 weeks), within 6 weeks
twice daily
Duque et al 2005 Uremic pruritus 20 (12 with Tacrolimus 0.1%, twice daily 100% relief in tacrolimus
tacrolimus, 8 and vehicle group
received vehicle)
Abbreviations: GvhD, graft versus host disease; QoL, quality of life.Therapeutics and Clinical Risk Management 2006:2(2) 217
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such as psoriasis and atopic dermatitis (Welsh et al 2004;
Eichmann 2005). Though the underlying origin may
frequently be identified, therapy is difficult due to the
increased resorption and sensitivity in this area. Due to our
findings, topical calcineurin inhibitors may be a safe
treatment alternative. Also, other types of localized and
generalized pruritus of unknown origin without primary skin
lesions could be influenced by topical calcineurin inhibitors.
However, the efficacy of therapy varied from 50% to 100%
concerning the reduction of the pruritus. Interestingly, in a
patient with xerosis and beginning exsiccation dermatitis,
an almost complete reduction (90% itch reduction) was
achieved.
Prurigo nodularis is not an own entity but a descriptive
term for chronic secondary scratch lesions due to therapy
refractory pruritus. In our patients, pruritus was induced by
mainly psychogenic and internal diseases and less by
cutaneous disorders. According to the severity of prurigo
Figure 2 Female 63-year-old patient with prurigo nodularis since 20 years (a).
After a 5 months therapy all skin lesions cleared and skin remained stable after
one month stopping the treatment (b).
nodularis, both calcineurin inhibitors achieved a significant
improvement of pruritus and skin lesions consisting of
papules and flat nodules. Thick nodules did not respond to
this therapy which is most likely due to decreased
penetration of the active substance. These results suggest
that calcineurin inhibitors may be helpful in a subgroup of
patients with prurigo nodularis. Further studies with larger
collectives of patients have to evaluate the efficacy of
tacrolimus and pimecrolimus in prurigo nodularis.
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